Chinese expert consensus on the clinical application of recombinant human thyroid-stimulating hormone (2025 edition)
-
Shen Chentian,
-
Gu Yushen,
-
Tan Hui,
-
Kuang Anren,
-
Li Sijin,
-
Li Yaming,
-
Wang Jing,
-
Jiang Ningyi,
-
Tan Jian,
-
Wang Zhuoying,
-
Liu Shaoyan,
-
Li Xiaoyi,
-
Fang Jugao,
-
Luo Dingcun,
-
Fan Youben,
-
Wang Hui,
-
Wang Yuetao,
-
Wang Xuemei,
-
Wang Feng,
-
Fu Wei,
-
Shi Feng,
-
Liu Xuegong,
-
Lü Zhongwei,
-
Xing Yan,
-
Li Lin,
-
Yang Hui,
-
Xin Jun,
-
Zhang Yifan,
-
Chen Yue,
-
Lin Yansong,
-
Ouyang Wei,
-
Yao Shuzhan,
-
Zhao Changjiu,
-
Zhao Xinming,
-
Gao Zairong,
-
Huang Dingde,
-
Wen Qiang,
-
Han Xingmin,
-
Lou Cen,
-
Miao Weibing,
-
Fan Wei,
-
Luo Quanyong,
-
Shi Hongcheng
-
-
Abstract
The recombinant human thyroid-stimulating hormone (rhTSH) can be used for differentiated thyroid cancer (DTC) preparation before 131I therapy, and follow-up. Since its approval by the American Food and Drug Administration (FDA) in 1998, rhTSH has been clinically used in European countries, the United States, and other countries for nearly 30 years. In April 2024, the first independently developed rhTSH agent in China was approved. Based on clinical experience and integrating evidence from domestic and international studies, an expert consensus on the application of rhTSH has been developed following thorough consultations among experts. The consensus offers evidence-based recommendations designed to guide the appropriate use of rhTSH in clinical practice.
-
-
DownLoad: